Paul M Hoesly, MD
Dermatology · Tigard
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 3 carriers
- Office
- 1
Offices
1 location · Mountain West Derm - Blackhart PLLC · 103 clinicians in this group
Hospitals listed: OHSU Hospital and Clinics. That is not proof they admit you there this week.
Plans that list them
21 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hoesly’s office at (503) 245-2415 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A170076 · Delinquent
Licence status: Delinquent · since 2020 · expires 2024-09-30 · Northwestern University Feinberg School of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- OHSU Hospital and ClinicsPortland, ORAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Oregon Health and Science University, which runs 2 hospitalsHome of Knight Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.31 (1.1 to 1.51), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.83 (5.37 to 8.29) · 3,784 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.733, Oct 2024 – Sep 2025
See every measure and the patient survey for OHSU Hospital and Clinics
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.31 (1.1 to 1.51) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.83 (5.37 to 8.29) · 3,784 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.733 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.38 (0.61 to 2.14) · 2,275 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 150.45 (118.94 to 181.96) · 340 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 197 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.7 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.7 · 273 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 3,434 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.07 to 0.43) · 7,501 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.06 to 0.42) · 7,980 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.42 (1.27 to 3.57) · 2,337 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (1.24 to 3.31) · 3,615 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.99 (7.55 to 14.42) · 2,153 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.35 (5.23 to 9.48) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.69 to 3.27) · 1,001 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.66 (0.18 to 1.14) · 6,661 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 56 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.838 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.8 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.936 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.381 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.174 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 180 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 320 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11.9 · 120 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 223 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.5 · 142 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.6 · 204 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.9 to 6.3) · 952 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.5 (8 to 11.4) · 952 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.1 to 15.4) · 1,483 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,425 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 24% of those asked)
| Cleanliness | 2 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$113,933
Medicare paid this office $113,933 for 434 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 259 | $23,661 | $71 |
| New patient visit (30+ min) | 159 | $13,429 | $84 |
| Destruction of skin growth, 1-14 growths | 113 | $13,006 | $102 |
| Destruction of precancer skin growth, 1 growth | 199 | $10,626 | $46 |
| Biopsy of related skin growth, first growth | 98 | $9,768 | $86 |
See all 17 services
| Short return visit (20+ min) | 259 | $23,661 | $71 |
| New patient visit (30+ min) | 159 | $13,429 | $84 |
| Destruction of skin growth, 1-14 growths | 113 | $13,006 | $102 |
| Destruction of precancer skin growth, 1 growth | 199 | $10,626 | $46 |
| Biopsy of related skin growth, first growth | 98 | $9,768 | $86 |
| Destruction of precancer skin growth, 2-14 growths | 159 | $8,663 | $7 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 20 | $7,042 | $293 |
| Destruction of precancer skin growth, 15 or more growths | 21 | $3,558 | $155 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 12 | $2,610 | $163 |
| New patient visit (45+ min) | 23 | $2,522 | $110 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 14 | $2,092 | $123 |
| Punch biopsy, first skin growth | 16 | $1,977 | $116 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 17 | $1,931 | $107 |
| Biopsy of related skin growth, each additional growth | 21 | $1,562 | $52 |
| Short return visit | 17 | $939 | $49 |
| Shaving of skin growth of body, arms, or legs, 0.5 cm or less | 11 | $930 | $85 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $10 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 12 | More than 66% of doctors who do this |
| Removal of skin lesions | 562 | More than 88% of doctors who do this |
| Removal or shaving of skin growth | 15 | More than 68% of doctors who do this |
| Skin biopsy | 205 | More than 85% of doctors who do this |
Who their Medicare patients are
434 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 12% · Women 46% · Also on Medicaid 8% · Health risk score 0.94. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 63% · Coronary heart disease 27% · Diabetes 23% · Chronic kidney disease 15% · Cancer 15% · Atrial fibrillation 13% · Depression 12% · Heart failure 10% · COPD 8% · Stroke 5% · Dementia 4%.
The office billed $282,375, Medicare allowed $161,713 and paid $113,933; for 2,558 services of 52 kinds; $318 of it was for drugs given in the office and $113,614 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 434 | 2,558 | 75 | 0.94 | $282,375 | $113,933 |
| 2023 | 292 | 1,936 | 75 | 0.92 | $208,723 | $95,256 |
| 2022 | 684 | 2,741 | 75 | 1.16 | $669,401 | $143,645 |
| 2021 | 709 | 3,748 | 74 | 1.16 | $961,642 | $194,188 |
| 2020 | 407 | 1,552 | 73 | 1.12 | $280,796 | $64,284 |
| 2019 | 297 | 1,069 | 72 | 0.93 | $127,292 | $45,654 |
| 2018 | 234 | 726 | 73 | 1.23 | $80,795 | $35,154 |
| 2017 | 351 | 1,119 | 75 | 1.24 | $92,166 | $53,550 |
| 2016 | 220 | 420 | 76 | 1.47 | $29,844 | $19,386 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Short return visit (20+ min) | 150 | $20,099 | $83 |
| New patient visit (30+ min) | 132 | $11,455 | $87 |
| Destruction of skin growth, 1-14 growths | 70 | $10,008 | $112 |
| Destruction of precancer skin growth, 1 growth | 141 | $8,972 | $48 |
| Biopsy of related skin growth, first growth | 63 | $7,332 | $99 |
| Destruction of precancer skin growth, 2-14 growths | 114 | $6,772 | $7 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 20 | $6,599 | $314 |
| New patient visit (45+ min) | 29 | $3,966 | $137 |
| Return visit (30+ min) | 23 | $3,217 | $119 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $2,315 | $178 |
| Punch biopsy, first skin growth | 14 | $2,204 | $130 |
| Biopsy of related skin growth, each additional growth | 23 | $1,821 | $54 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 13 | $1,659 | $128 |
| Short return visit | 13 | $852 | $57 |
| Injection into skin growth, 1-7 growths | 13 | $693 | $38 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $20 | None |
2022: 18 services
| Short return visit (20+ min) | 395 | $31,203 | $63 |
| Destruction of skin growth, 1-14 growths | 139 | $14,395 | $91 |
| Destruction of precancer skin growth, 15 or more growths | 91 | $13,451 | $133 |
| Biopsy of related skin growth, first growth | 158 | $13,438 | $78 |
| Destruction of precancer skin growth, 1 growth | 234 | $10,732 | $41 |
| Return visit (30+ min) | 92 | $10,269 | $100 |
| New patient visit (30+ min) | 115 | $9,660 | $83 |
| Destruction of precancer skin growth, 2-14 growths | 174 | $4,953 | $6 |
| New patient visit (45+ min) | 33 | $4,793 | $145 |
| Biopsy of related skin growth, each additional growth | 54 | $3,827 | $46 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 15 | $3,712 | $247 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 21 | $3,053 | $145 |
| Punch biopsy, first skin growth | 27 | $2,995 | $111 |
| Short return visit | 62 | $2,923 | $42 |
| New patient visit (15+ min) | 67 | $2,254 | $34 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 13 | $1,784 | $137 |
| Injection into skin growth, 1-7 growths | 22 | $1,248 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 23 | $30 | None |
2021: 20 services
| Short return visit (20+ min) | 386 | $41,339 | $71 |
| Biopsy of related skin growth, first growth | 212 | $18,927 | $77 |
| Destruction of skin growth, 1-14 growths | 166 | $17,404 | $88 |
| Destruction of precancer skin growth, 15 or more growths | 85 | $14,803 | $135 |
| Return visit (30+ min) | 116 | $14,484 | $100 |
| Destruction of precancer skin growth, 1 growth | 258 | $13,240 | $41 |
| New patient visit (15+ min) | 150 | $8,811 | $59 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 33 | $8,643 | $247 |
| New patient visit (30+ min) | 96 | $7,672 | $80 |
| Destruction of precancer skin growth, 2-14 growths | 195 | $7,048 | $5 |
| Short return visit | 88 | $4,026 | $40 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 29 | $3,469 | $108 |
| Biopsy of related skin growth, each additional growth | 54 | $3,421 | $43 |
| Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | 21 | $3,220 | $153 |
| New patient visit (45+ min) | 27 | $3,088 | $114 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 20 | $2,910 | $145 |
| Punch biopsy, first skin growth | 25 | $2,524 | $101 |
| Injection into skin growth, 1-7 growths | 23 | $1,384 | $38 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 11 | $1,345 | $122 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 18 | $43 | None |
2020: 11 services
| Return visit (30+ min) | 116 | $10,967 | $85 |
| Short return visit (20+ min) | 146 | $9,271 | $53 |
| New patient visit (30+ min) | 84 | $6,752 | $80 |
| Destruction of precancer skin growth, 1 growth | 136 | $5,957 | $42 |
| Biopsy of related skin growth, first growth | 66 | $4,899 | $71 |
| Destruction of skin growth, 1-14 growths | 56 | $4,737 | $80 |
| New patient visit (15+ min) | 66 | $3,120 | $47 |
| Destruction of precancer skin growth, 2-14 growths | 102 | $3,051 | $5 |
| Punch biopsy, first skin growth | 17 | $1,627 | $90 |
| Destruction of precancer skin growth, 15 or more growths | 13 | $1,490 | $115 |
| Short return visit | 17 | $648 | $38 |
2019: 10 services
| Short return visit (20+ min) | 107 | $7,628 | $54 |
| New patient visit (30+ min) | 83 | $6,198 | $75 |
| Destruction of skin growth, 1-14 growths | 53 | $5,326 | $78 |
| New patient visit (15+ min) | 97 | $5,152 | $53 |
| Return visit (30+ min) | 52 | $4,653 | $82 |
| Destruction of precancer skin growth, 1 growth | 85 | $3,599 | $38 |
| Biopsy of related skin growth, first growth | 37 | $2,789 | $68 |
| Destruction of precancer skin growth, 2-14 growths | 56 | $1,525 | $4 |
| Punch biopsy, first skin growth | 16 | $1,413 | $88 |
| New patient visit (10+ min) | 14 | $436 | $31 |
2018: 12 services
| Short return visit (20+ min) | 99 | $5,172 | $47 |
| Biopsy of single growth of skin and/or tissue | 66 | $4,253 | $62 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 16 | $3,652 | $215 |
| Return visit (30+ min) | 43 | $3,444 | $78 |
| Destruction of skin growth, 1-14 growths | 32 | $2,534 | $67 |
| New patient visit (30+ min) | 30 | $2,358 | $79 |
| New patient visit (15+ min) | 45 | $2,299 | $51 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 23 | $1,596 | $64 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 17 | $1,255 | $66 |
| Destruction of precancer skin growth, 1 growth | 43 | $1,163 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $588 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 14 | $552 | $25 |
2017: 11 services
| Short return visit (20+ min) | 196 | $12,001 | $48 |
| Return visit (30+ min) | 113 | $9,001 | $72 |
| Biopsy of single growth of skin and/or tissue | 99 | $6,414 | $61 |
| Destruction of skin growth, 1-14 growths | 42 | $3,157 | $72 |
| Destruction of precancer skin growth, 1 growth | 72 | $2,616 | $34 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 30 | $2,563 | $73 |
| New patient visit (30+ min) | 32 | $2,512 | $78 |
| New patient visit (15+ min) | 34 | $1,787 | $53 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 16 | $1,734 | $102 |
| Destruction of precancer skin growth, 2-14 growths | 52 | $1,154 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 19 | $598 | $25 |
2016: 7 services
| Short return visit (20+ min) | 125 | $7,455 | $50 |
| Return visit (30+ min) | 52 | $4,312 | $80 |
| New patient visit (30+ min) | 22 | $1,679 | $76 |
| New patient visit (15+ min) | 26 | $1,421 | $55 |
| Biopsy of single growth of skin and/or tissue | 18 | $1,378 | $73 |
| Destruction of precancer skin growth, 1 growth | 17 | $649 | $38 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $440 | $4 |
Drugs they prescribed that Part D paid
$103,092
Pharmacies billed $103,092 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 598) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
577 generic and 21 brand-name prescriptions · $103,092 in drug cost · 17 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 35 | $3,686 | $53 |
| Fluorouracil | 25 | $2,557 | $91 |
| Fluocinonide | 36 | $2,113 | $38 |
| Ketoconazole | 51 | $1,536 | $13 |
| Tacrolimus | 13 | $1,076 | $60 |
See all 12 drugs
| Clobetasol Propionate | 35 | $3,686 | $53 |
| Fluorouracil | 25 | $2,557 | $91 |
| Fluocinonide | 36 | $2,113 | $38 |
| Ketoconazole | 51 | $1,536 | $13 |
| Tacrolimus | 13 | $1,076 | $60 |
| Betamethasone Diprop Augmented | 24 | $1,038 | $23 |
| Desonide | 14 | $1,019 | $60 |
| Triamcinolone Acetonide | 72 | $960 | $10 |
| Metronidazole | 11 | $634 | $40 |
| Ciclopirox | 14 | $451 | $20 |
| Doxycycline Hyclate | 13 | $197 | $15 |
| Hydrocortisone | 18 | $110 | $3 |
Year by year
| 2024 | 598 | 265 | 0% (0) | 4% | $103,092 |
| 2023 | 398 | 194 | 0% (0) | 4% | $28,429 |
| 2022 | 617 | 262 | 0% (0) | None | $319,830 |
| 2021 | 641 | 260 | 0% (0) | None | $225,376 |
| 2020 | 422 | 206 | 0% (0) | 5% | $39,722 |
| 2019 | 456 | 201 | None | 5% | $17,749 |
| 2018 | 232 | 118 | 0% (0) | 7% | $26,649 |
| 2017 | 302 | 129 | 0% (0) | 8% | $66,587 |
| 2016 | 291 | 134 | None | None | $52,704 |
| 2015 | 107 | 67 | 0% (0) | 20% | $15,730 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Clobetasol Propionate | 40 | $2,155 | $54 |
| Fluorouracil | 14 | $1,296 | $93 |
| Metronidazole | 14 | $1,261 | $90 |
| Triamcinolone Acetonide | 84 | $1,129 | $13 |
| Ketoconazole | 49 | $1,025 | $21 |
| Fluocinonide | 22 | $947 | $43 |
| Betamethasone Diprop Augmented | 50 | $855 | $17 |
| Doxycycline Hyclate | 21 | $792 | $38 |
| Ciclopirox | 16 | $418 | $26 |
| Hydrocortisone | 15 | $63 | $4 |
2022: 17 drugs
| Cosentyx Pen (2 Pens) | 14 | $94,695 | $6,764 |
| Humira | 12 | $80,250 | $6,687 |
| Fluorouracil | 35 | $3,397 | $97 |
| Betamethasone Diprop Augmented | 72 | $1,933 | $27 |
| Ketoconazole | 85 | $1,799 | $21 |
| Tacrolimus | 13 | $1,790 | $138 |
| Metronidazole | 22 | $1,727 | $79 |
| Fluocinonide | 33 | $1,385 | $42 |
| Clobetasol Propionate | 41 | $1,289 | $31 |
| Azelaic Acid | 13 | $1,270 | $98 |
| Doxycycline Hyclate | 21 | $1,084 | $52 |
| Triamcinolone Acetonide | 88 | $955 | $11 |
| Hydroxychloroquine Sulfate | 11 | $627 | $57 |
| Betamethasone Dipropionate | 12 | $623 | $52 |
| Clindamycin Phosphate | 11 | $606 | $55 |
| Prednisone | 21 | $105 | $5 |
| Hydrocortisone | 16 | $77 | $5 |
2021: 13 drugs
| Humira | 17 | $103,966 | $6,116 |
| Dupixent | 17 | $55,196 | $3,247 |
| Fluorouracil | 40 | $3,532 | $88 |
| Metronidazole | 29 | $2,349 | $81 |
| Clobetasol Propionate | 41 | $1,881 | $46 |
| Ketoconazole | 80 | $1,876 | $23 |
| Fluocinonide | 37 | $1,858 | $50 |
| Betamethasone Diprop Augmented | 66 | $1,259 | $19 |
| Triamcinolone Acetonide | 103 | $1,156 | $11 |
| Doxycycline Hyclate | 24 | $836 | $35 |
| Clindamycin Phosphate | 12 | $602 | $50 |
| Hydrocortisone | 32 | $171 | $5 |
| Prednisone | 13 | $86 | $7 |
2020: 9 drugs
| Fluocinonide | 27 | $1,558 | $58 |
| Clobetasol Propionate | 28 | $1,445 | $52 |
| Ketoconazole | 50 | $1,243 | $25 |
| Betamethasone Diprop Augmented | 69 | $1,239 | $18 |
| Triamcinolone Acetonide | 79 | $851 | $11 |
| Doxycycline Hyclate | 32 | $806 | $25 |
| Valacyclovir | 15 | $386 | $26 |
| Hydrocortisone | 28 | $128 | $5 |
| Hydroxyzine | 11 | $118 | $11 |
2019: 9 drugs
| Fluorouracil | 17 | $1,654 | $97 |
| Ketoconazole | 52 | $1,446 | $28 |
| Betamethasone Diprop Augmented | 63 | $1,215 | $19 |
| Fluocinonide | 18 | $1,078 | $60 |
| Clobetasol Propionate | 19 | $966 | $51 |
| Triamcinolone Acetonide | 98 | $942 | $10 |
| Doxycycline Hyclate | 27 | $729 | $27 |
| Hydrocortisone | 44 | $279 | $6 |
| Prednisone | 17 | $88 | $5 |
2018: 6 drugs
| Fluorouracil | 27 | $2,838 | $105 |
| Metronidazole | 14 | $880 | $63 |
| Fluocinonide | 17 | $575 | $34 |
| Ketoconazole | 23 | $556 | $24 |
| Triamcinolone Acetonide | 34 | $328 | $10 |
| Hydrocortisone | 19 | $89 | $5 |
2017: 11 drugs
| Acitretin | 14 | $5,531 | $395 |
| Fluorouracil | 41 | $5,115 | $125 |
| Clobetasol Propionate | 22 | $3,362 | $153 |
| Fluocinonide | 19 | $1,132 | $60 |
| Ketoconazole | 37 | $995 | $27 |
| Hydroxychloroquine Sulfate | 11 | $756 | $69 |
| Triamcinolone Acetonide | 38 | $464 | $12 |
| Dapsone | 15 | $463 | $31 |
| Doxycycline Monohydrate | 12 | $364 | $30 |
| Hydrocortisone | 15 | $80 | $5 |
| Prednisone | 11 | $76 | $7 |
2016: 7 drugs
| Fluorouracil | 35 | $5,963 | $170 |
| Clobetasol Propionate | 31 | $3,909 | $126 |
| Fluocinonide | 19 | $991 | $52 |
| Dapsone | 13 | $598 | $46 |
| Ketoconazole | 16 | $534 | $33 |
| Triamcinolone Acetonide | 29 | $377 | $13 |
| Prednisone | 18 | $121 | $7 |
2015: 3 drugs
| Clobetasol Propionate | 18 | $3,037 | $169 |
| Fluorouracil | 18 | $2,703 | $150 |
| Triamcinolone Acetonide | 11 | $139 | $13 |
Money from drug and device companies
$25 in 2025
| 2025 | 1 | 1 | None | $25 |
| 2024 | 8 | 31 | None | $635 |
| 2023 | 9 | 34 | None | $693 |
| 2022 | 7 | 12 | None | $262 |
| 2021 | 1 | 2 | $3,600 | $3,600 |
| 2019 | 2 | 3 | None | $154 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Dupixent | $25 | 1 payment
|
See the published payment
| Regeneron Healthcare Solutions | Meals · 2025-04-17 | Dupixent | $25 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $635
| Abbvie | Skyrizi | $325 | 18 payments
|
| Almirall | Klisyri | $52 | 2 payments
|
| Janssen Biotech | Tremfya | $49 | 2 payments
|
| Incyte | Opzelura | $49 | 2 payments
|
| Pfizer | Eucrisa | $49 | 2 payments
|
| Lilly USA | Ebglyss | $44 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $43 | 2 payments
|
| Galderma Laboratories L.P. | None | $23 | 1 payment
|
2023: $693
| Abbvie | Skyrizi | $357 | 19 payments
|
| Regeneron Healthcare Solutions | Dupixent | $87 | 3 payments
|
| Genzyme | Dupixent | $82 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $72 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $24 | 1 payment
|
| Incyte | Opzelura | $22 | 1 payment
|
| Galderma Laboratories L.P. | None | $19 | 1 payment
|
| Janssen Biotech | Remicade | $15 | 1 payment
|
| LEO Pharma | Adbry | $15 | 1 payment
|
2022: $262
| Abbvie | Skyrizi | $77 | 4 payments
|
| LEO Pharma | Adbry | $60 | 3 payments
|
| STRATA Skin Sciences | Xtrac | $47 | 1 payment
|
| Lilly USA | Taltz | $23 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $21 | 1 payment
|
| Pfizer | Eucrisa | $17 | 1 payment
|
| Galderma Laboratories L.P. | Epsolay | $16 | 1 payment
|
2021: $3,600
| Novartis Pharmaceuticals | Cosentyx | $3,600 | 2 payments
|
2019: $154
| AbbVie | Humira | $121 | 1 payment
|
| Janssen Biotech | Remicade | $33 | 2 payments
|
Professional record
- NPI
- 1376954529
- Licence
- CA A170076California A170076: Delinquent · expires 2024-09-30
- Trained
- Northwestern University Feinberg Medical School, 2014
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 3301 C St Ste 1300, Sacramento, CA, 95816
- NPI first listed
- 2014-05-09
- NPI last updated
- 2024-03-13
- NPI record certified
- 2024-03-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 525 South Dr Ste 115, Mountain View, CA, 94040 · 3301 C St Ste 1400, Sacramento, CA, 95816 · 2420 Samaritan Dr, San Jose, CA, 95124